TASCENSO ODT® (fingolimod)
0.25 mg and 0.5 mg
What is TASCENSO ODT?
TASCENSO orally disintegrating tablet (ODT) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.1
It is the same proven fingolimod you might be familiar with, but it comes in a unique ODT formulation.1
At Cycle, we know that life-changing treatments need life-improving support to match. That’s why we created Cycle Vita, delivering individualized product support every step of the way with TASCENSO ODT.

Support available to you with TASCENSO ODT
Start your TASCENSO ODT enrollment here
Download and print the enrolment form, share it with your doctor and discuss why you think TASCENSO ODT may be suited to your needs.
The first steps
Your Cycle Vita team will quickly get to work with your insurance provider to help you understand your coverage.
We will coordinate seamlessly between different parties, such as insurance companies, doctors, and pharmacists to help you with your prior authorization and document requirements.
We will route your TASCENSO ODT therapy to the appropriate specialty pharmacy and follow-up to ensure swift shipment of your medication.
Additional assistance, when required, thoughout your journey
Our Cycle Vita team has decades of experience supporting patients with MS.
If you are not currently taking a fingolimod product, eligible patients will require baseline assessments (such as blood work, an ECG or eye exam) prior to taking TASCENSO ODT and a first dose observation the first time you take the product.1 FDOs are available in-home or at a neutral location if necessary, through the TASCENSO Time Program.
Co-pay assistance*
If you have commercial insurance, you may be eligible for the Cycle Vita Co-pay assistance Program. Commercially insured eligible patients may pay as little as $0. Please contact our Access Specialists to find out more about this and other programs that may be available to you (such as the Bridge Program).
If you are taking another fingolimod treatment, a free supply of TASCENSO ODT is available while we secure appropriate benefit verification and prior authorization. It may also be requested if you experience a temporary disruption in therapy due to insurance coverage.
Our Registered Clinicians can provide you with training to help you keep on top of your medication schedule.
Translation services are available on request.
In some cases, an appeal may be needed. Where this is the case, our experienced team will work with your insurer and doctor to understand the requirements and help you with any TASCENSO ODT reimbursement gaps.
If you agree, our proactive team will remind your doctor when your TASCENSO ODT prescription needs to be renewed, in a timely manner, to ensure an uninterrupted supply of your therapy.
What is multiple sclerosis (MS)?
The exact cause of MS is unknown. Scientists believe it is triggered by several different factors and there is ongoing research to identify the exact cause.2
No two MS patients are the same, and symptoms vary from person to person.3 Some of the main symptoms include problems with vision, fatigue, numbness, pain and bowel or bladder problems.3 Not everyone will experience all of these symptoms.
Diagnosis can be life altering and incredibly emotional for you and your family. There’s a lot to take in and think about, and every patient with MS has a different experience. At Cycle Vita, we are here to support you, for life.
Resources
Footnote
*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.
TASCENSO ODT® is a registered trademark of Handa Neuroscience, LLC.
References
- TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.
- National Multiple Sclerosis Society (2022) What Causes MS? Available at https://www.nationalmssociety.org/What-is-MS/What-Causes-MS (Accessed: December 6th 2022)
- National Multiple Sclerosis Society (2022) MS Signs & Symptoms. Available at https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms (Accessed: December 6th 2022)